NAD+ Mechanism of Action — Sirtuins, PARPs & CD38 in

*Cellular pharmacology of NAD+ supplementation: redox cofactor role, sirtuin and PARP substrate function, CD38 consumption pathway, and the case for precursor (NR/NMN) vs direct NAD+ administration.*

Research Use Only. All material on this page is provided strictly for in vitro and in vivo laboratory research purposes. It is not medical advice and is not intended for human or veterinary therapeutic use.

Overview

Nicotinamide adenine dinucleotide (NAD+) is a central redox cofactor required for hundreds of dehydrogenase reactions and the substrate for three major enzyme classes: sirtuins, PARPs and CD38. Tissue NAD+ levels decline with age across all measured human tissues — the empirical basis for restoration research.

Redox Cofactor Role

NAD+/NADH cycling is central to glycolysis, the TCA cycle and oxidative phosphorylation. Each glucose molecule yields net 10 NADH; the electron-transport chain regenerates NAD+ via Complex I. NAD+ availability is rate-limiting for oxidative metabolism under high energy demand.

Sirtuin Substrate Function

• SIRT1 (nuclear) — deacetylates p53, FOXO, PGC-1α — metabolic and stress-response regulation
• SIRT3 (mitochondrial) — deacetylates dozens of mitochondrial proteins, regulating fatty-acid oxidation and ROS handling
• SIRT6 (nuclear) — telomere maintenance, glucose homeostasis
• All sirtuins consume NAD+ stoichiometrically per deacetylation reaction

PARP Substrate Function

Poly(ADP-ribose) polymerases (PARP1, PARP2) consume NAD+ during DNA-damage repair. High PARP activity under chronic genotoxic stress (UV, inflammation, aging) is a major NAD+ sink and is hypothesised to contribute to age-related NAD+ decline.

CD38 Consumption

CD38 is a NAD+-glycohydrolase whose expression increases with age and inflammation. CD38 inhibition restores tissue NAD+ in preclinical models and is an active drug-development target.

Direct NAD+ vs Precursors

• NMN, NR: oral precursors with documented plasma uptake and tissue NAD+ elevation in human trials
• IV NAD+: direct administration; standard research protocols use slow infusion to limit flushing
• SC NAD+: local depot administration; emerging research route
• Precursors are easier to dose; direct NAD+ achieves faster systemic elevation

Frequently Asked Research Questions

Why do NAD+ levels decline with age?

The proposed primary drivers are increased CD38 expression (NAD+ consumption), chronic PARP activation from accumulated DNA damage, and reduced biosynthetic capacity. Each has been targeted independently in restoration research.

Is NAD+ supplementation the same as NMN or NR?

Mechanistically related but pharmacokinetically distinct. NMN and NR are precursors that enter the salvage pathway to generate NAD+ inside cells. Direct NAD+ administration produces faster systemic elevation but is harder to dose and typically requires IV or slow SC routes.

What do sirtuins do with NAD+?

Sirtuins are NAD+-dependent deacetylases. Each deacetylation reaction consumes one NAD+ and produces nicotinamide + O-acetyl-ADP-ribose. Sirtuin targets include p53, FOXO, PGC-1α and dozens of mitochondrial proteins regulated by SIRT3.

References

1. Drucker DJ. *Mechanisms of action and therapeutic application of GLP-1.* Cell Metab. 2018.

1. Coskun T, et al. *LY3298176 (tirzepatide) — discovery of a dual GIP/GLP-1 agonist.* Mol Metab. 2018.

1. Sikiric P, et al. *Stable gastric pentadecapeptide BPC-157.* Curr Pharm Des. 2018.

1. Goldstein AL, Hannappel E. *Thymosin β4 — actin sequestering and tissue repair.* Ann N Y Acad Sci. 2007.

1. Falutz J, et al. *Tesamorelin in HIV-associated lipodystrophy.* N Engl J Med. 2007.

1. Pfaus JG, et al. *Bremelanotide — central melanocortin agonism.* Curr Sex Health Rep. 2007.

1. Khavinson VK, et al. *Epitalon — pineal-tetrapeptide telomerase activation.* Bull Exp Biol Med. 2003.

1. Imai S, Guarente L. *NAD+ and sirtuins in aging and disease.* Trends Cell Biol. 2014.